Itay&biond develops a drug discovery platform to establish the next generation of treatments for Autism Spectrum Disorders and other Psychiatric and Neurological Dysfunctions.
These compounds will be going through a unique and patented estimation of their clinical efficacy using the novel technology that underlies our drug discovery platform. The most promising compounds will go on for pre-clinical study.
Our business opportunities include licensing, co-development, and sells of drugs developed up to pre-IND.
Established in 2021, Itay&Biond is an innovative company that develops a drug discovery platform for the treatment of Autism Spectrum Disorders (ASD).
Itay&Biond is led by a strong and experienced team of professionals and scientists with expert know-how and experience in the biologics pharma industry.
Itay&Biond delivers an innovative, scalable and cost-effective biologics model based on AI-driven predictive analytics and advanced biotechnology methods.
Together With Hadassah Hospital In Jerusalem, We Are Currently Validating Our Drug Discovery Platform Using Samples Of 200 Patients.
Itay&Biond holds two issued US patents with PCT extensions. Additional patent applications are in process.
Our biologics drug discovery platform has the potential to treat ASD in addition to a wide range of previously untreatable diseases.
Promising preliminary results of the RNA-based molecule for treating sub-population of Autism spectrum disorders
RNA-based molecule for treating sub-population of Autism spectrum disorders
Novel scalable non-invasive sample collection device
200 samples of ASD patients
Hadassah Hospital
Growing hundred of ASD patients brain organoids
Scalable drug screening and discovery platform
English 
Arabic